MiNK Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

New york, april 08, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced the presentation of data from mink-215, an investigational il-15 armored fibroblast activation protein (fap) targeting car-inkt cell therapy, at the american association for cancer research (aacr) meeting in san diego, ca.

New york, march 21, 2024 (globe newswire) --  mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the fourth quarter and full-year 2023. mink executives will host a conference call and webcast at 8:30 a.m. et to discuss the results and to provide a corporate update.

New york, march 07, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its fourth quarter and year-end 2023 financial results before the market opens on thursday, march 21, 2024. mink executives will host a conference call and webcast at 8:30 a.m. et that morning to discuss the results and to provide a corporate update.

Mink-215 eradicated tumor cells in human organoid mss colorectal cancer liver metastases model mink-215 eradicated tumor cells in human organoid mss colorectal cancer liver metastases model

New york, jan. 30, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced the publication of a case report in oncogene from its phase 1/2 study in patients with advanced solid tumors where one infusion of agent-797 in gastric cancer refractory to anti-pd1 led to a durable confirmed partial response, highlighting the unique potential of inkt cells to overcome resistance to immune checkpoint inhibitors (icis).

MiNK Therapeutics, Inc. (INKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agenT-797's distinct mechanism of action in solid tumors. A poster will be presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting on November 1-5, 2023.

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer and President, will participate in the following upcoming investor conferences:

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its virtual-only Annual Meeting of Shareholders will be held on Tuesday, June 13, 2023, at 10:30 AM ET.

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Relations Jennifer Buell – President and Chief Executive Officer Marc Van Dijk – Chief Scientific Officer Christine Klaskin – Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar – H.C. Wainwright Jack Allen – Baird Matthew Phipps – William Blair Operator Ladies and gentlemen, thank you for standing by.

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

After losing some value lately, a hammer chart pattern has been formed for MiNK Therapeutics, Inc. (INKT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18.